发明名称 |
Rosiglitazone formulations |
摘要 |
Rosiglitazone is a drug used to treat type 2 diabetes. Methods for the formation of amorphous rosiglitazone and formulations comprising the amorphous rosiglitazone are described. Other formulations include pulsed-release formulations and formulations for retention in the stomach and upper gastrointestinal tract. Controlled-release dosage form include those wherein the maximum plasma concentration of rosiglitazone occurs greater than one hour after administration to a human and/or wherein less than 75 percent by weight of the rosiglitazone is released at 1 hour after immersion in simulated gastric fluid.
|
申请公布号 |
US2005163837(A1) |
申请公布日期 |
2005.07.28 |
申请号 |
US20040021491 |
申请日期 |
2004.12.23 |
申请人 |
BOEHM GARTH;DUNDON JOSEPHINE |
发明人 |
BOEHM GARTH;DUNDON JOSEPHINE |
分类号 |
A61K9/00;A61K9/14;A61K9/16;A61K9/20;A61K9/24;A61K9/28;A61K31/426;A61K31/4439;(IPC1-7):A61K31/426 |
主分类号 |
A61K9/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|